Shared Decision Making for Chronic Kidney Disease
(DIAL-SDM Trial)

Recruiting in Palo Alto (17 mi)

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Rochester

No Placebo Group

Trial Summary

What is the purpose of this trial?

This trial aims to improve decision-making about dialysis for older patients with severe chronic kidney disease. Doctors will be trained to communicate better, and patients will receive coaching to help them express their treatment preferences. The goal is to ensure that treatment decisions align with the patients' values and improve their quality of life.

Eligibility Criteria

This trial is for patients aged 65 or older with advanced chronic kidney disease (stages 4 or 5) who haven't yet decided on dialysis and speak English. Their nephrologist must be part of the study and working at Strong Memorial Hospital. Caregivers involved in patient care can also participate.

Inclusion Criteria

For nephrologist: Member of Strong nephrology group working at Strong Memorial Hospital, Treat patients with CKD

You are 65 years or older, have severe kidney disease, have seen a kidney doctor, speak English, have not attended a class about dialysis, and have not decided about starting dialysis.

I am a caregiver, 21 or older, helping someone with their health care.

Exclusion Criteria

For Nephrologists: Expecting to leave in six months.

You have already met with a palliative care doctor or are in hospice care, are currently receiving dialysis, are in the hospital, have trouble thinking clearly, or do not speak English.

I am a caregiver by profession and have cognitive impairment.

Treatment Details

Interventions

DIAL-SDM (Behavioral Intervention)

Trial OverviewThe trial tests a shared decision-making program (DIAL-SDM) against usual care for kidney disease treatment choices. Nephrologists will get communication training, while patients receive coaching to help them discuss their treatment preferences effectively.

Participant Groups

2Treatment groups

Experimental Treatment

Group I: interventionExperimental Treatment1 Intervention

Group II: controlExperimental Treatment1 Intervention

Usual care